[go: up one dir, main page]

MA26668A1 - ACTIVATEURS DE hPPARy ET hPPARa - Google Patents

ACTIVATEURS DE hPPARy ET hPPARa

Info

Publication number
MA26668A1
MA26668A1 MA25716A MA25716A MA26668A1 MA 26668 A1 MA26668 A1 MA 26668A1 MA 25716 A MA25716 A MA 25716A MA 25716 A MA25716 A MA 25716A MA 26668 A1 MA26668 A1 MA 26668A1
Authority
MA
Morocco
Prior art keywords
hppary
hppara
activators
Prior art date
Application number
MA25716A
Other languages
English (en)
Inventor
Loren Collins Jon
Alan Oplinger Jeffrey
Mark Willson Timothy
Dezube Milana
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA26668A1 publication Critical patent/MA26668A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA25716A 1998-08-07 1999-08-05 ACTIVATEURS DE hPPARy ET hPPARa MA26668A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9817118.4A GB9817118D0 (en) 1998-08-07 1998-08-07 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
MA26668A1 true MA26668A1 (fr) 2004-12-20

Family

ID=10836805

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25716A MA26668A1 (fr) 1998-08-07 1999-08-05 ACTIVATEURS DE hPPARy ET hPPARa

Country Status (31)

Country Link
US (1) US6498174B1 (fr)
EP (1) EP1102757B1 (fr)
JP (1) JP2002522426A (fr)
KR (1) KR20010085340A (fr)
CN (1) CN1321152A (fr)
AP (1) AP2001002066A0 (fr)
AR (1) AR020001A1 (fr)
AT (1) ATE264313T1 (fr)
AU (1) AU5731099A (fr)
BR (1) BR9912866A (fr)
CA (1) CA2339773A1 (fr)
CO (1) CO5070570A1 (fr)
CZ (1) CZ2001490A3 (fr)
DE (1) DE69916457T2 (fr)
EA (1) EA200100105A1 (fr)
EE (1) EE200100074A (fr)
ES (1) ES2220110T3 (fr)
GB (1) GB9817118D0 (fr)
HR (1) HRP20010095A2 (fr)
HU (1) HUP0103469A3 (fr)
ID (1) ID29543A (fr)
IL (1) IL141248A0 (fr)
IS (1) IS5840A (fr)
MA (1) MA26668A1 (fr)
NO (1) NO20010628L (fr)
PE (1) PE20000947A1 (fr)
PL (1) PL345882A1 (fr)
SK (1) SK1962001A3 (fr)
TR (1) TR200100372T2 (fr)
WO (1) WO2000008002A1 (fr)
ZA (1) ZA200100983B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1206457T3 (da) * 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER
EP1589006A1 (fr) * 1999-09-22 2005-10-26 Bristol-Myers Squibb Company Dérivés d'oxa- ou de thiazole utiles comme agents antidiabétiques et antiobésité
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TWI260321B (en) * 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
GB0002667D0 (en) * 2000-02-04 2000-03-29 Glaxo Group Ltd medicamesnts
US20040072838A1 (en) 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
WO2002076959A1 (fr) * 2001-03-23 2002-10-03 Takeda Chemical Industries, Ltd. Derive heterocyclique a cinq membres d'acide alcanoique
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
NZ529033A (en) 2001-05-15 2005-06-24 F Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes
PL367639A1 (en) 2001-05-29 2005-03-07 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic compound and medicinal use thereof
MXPA03010867A (es) * 2001-05-29 2004-02-27 Kyoto Pharma Ind Nuevos derivados heterociclicos y uso farmaceutico de los mismos.
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200300681A (en) * 2001-11-12 2003-06-16 Ono Pharmaceutical Co Carboxylic acid derivative compound and medicament containing same as active ingredient
WO2003059895A1 (fr) * 2002-01-17 2003-07-24 Toaeiyo Ltd. Derives d'acide halogenobenzylaminopropionique
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
KR100474202B1 (ko) * 2002-05-04 2005-03-08 강헌중 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체
ATE372990T1 (de) 2002-07-03 2007-09-15 Hoffmann La Roche Oxazolderivat und deren verwendung als insulinsensibilisatoren
AU2003259131A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
BR0313946A (pt) 2002-08-30 2005-07-12 Hoffmann La Roche Compostos, processo para a manufatura destes compostos, composições farmacêuticas que compreendem os mesmos, métodos para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppara(alfa) e/ou ppary, utilização dos compostos e/ou do método
RU2296759C2 (ru) 2002-09-12 2007-04-10 Ф.Хоффманн-Ля Рош Аг N-замещенные 1н-индол-5-пропионовые кислоты, фармацевтическая композиция, содержащая эти соединения, и их применение (варианты)
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
ES2312819T3 (es) 2002-11-25 2009-03-01 F. Hoffmann-La Roche Ag Derivados de indolilo.
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
RU2342362C2 (ru) * 2002-11-26 2008-12-27 Шэньчжэнь Чипскрин Байосайенсиз Лтд. Замещенные производные арилалкановой кислоты как пан агонисты рапп с высокой антигипергликемической и антигиперлипидемической активностью
US7192970B2 (en) 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
BRPI0411509A (pt) 2003-06-20 2006-07-25 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização
MXPA05013904A (es) 2003-06-20 2006-02-24 Hoffmann La Roche Derivados de pirido[2,1-a] isoquinolinas como inhibidores de dipeptidil-peptidasa iv(dpp-iv).
BRPI0510715A (pt) 2004-05-06 2007-11-20 Univ California enaminonas substituìdas, seus derivados e usos destas
CN100467456C (zh) 2004-05-24 2009-03-11 北京摩力克科技有限公司 作为hPPARα和/或hPPARγ激活剂的α-哌嗪取代的苯丙酸衍生物
CN100436430C (zh) * 2004-05-24 2008-11-26 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
CN100344618C (zh) 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N-芳丙烯酰基取代的酪氨酸衍生物
CN1896069B (zh) * 2005-07-15 2011-10-05 中国科学院上海药物研究所 一类取代噻唑-4酮化合物、制备方法和用途
CN101007790B (zh) * 2006-01-27 2011-03-30 北京摩力克科技有限公司 草氨酸衍生物、其制备方法和医药用途
CN101443330B (zh) * 2006-06-13 2012-12-19 上海海和药物研究开发有限公司 杂环非核苷类化合物及其制备方法、药物组合物和作为抗病毒抑制剂的用途
GB0719180D0 (en) 2007-10-02 2007-11-14 Cambrex Karlskoga Ab New process
EP2135865A1 (fr) 2008-06-17 2009-12-23 Bayer CropScience AG Acides de vinaigre substitués 1-(diazinyle)pyrazole-4-yl, leur procédé de fabrication et d'utilisation en tant qu'herbicides et régulateurs de croissance de plantes
EP2194052A1 (fr) 2008-12-06 2010-06-09 Bayer CropScience AG Acides de vinaigre 1-(thiazolyl) et 1-(Isothiazolyl)pyrazole-4-yl substitués, leur procédé de fabrication et d'utilisation en tant qu'herbicides et régulateurs de croissance des plantes
WO2011073098A1 (fr) 2009-12-15 2011-06-23 Bayer Cropscience Ag Acides 1-(hétéroaryl)-pyrazol-4-yl-acétiques, procédés de production et utilisation desdits acides comme herbicides et régulateurs de la croissance des plantes
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
WO2022052982A1 (fr) * 2020-09-14 2022-03-17 昭明泽康(北京)生物医药科技有限公司 UTILISATION DE LIGAND PPARα (RÉCEPTEUR ACTIVÉ PAR LE PROLIFÉRATEUR DE PEROXYSOME α) DANS LA PRÉPARATION DE MÉDICAMENTS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US6062509A (en) 1994-12-23 2000-05-16 Hexcel Corporation Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports
JPH08325263A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規2−アミノ−3−フェニルプロピオン酸誘導体
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
AU740444B2 (en) * 1996-08-19 2001-11-01 Japan Tobacco Inc. Propionic acid derivatives and use thereof

Also Published As

Publication number Publication date
DE69916457D1 (de) 2004-05-19
HUP0103469A3 (en) 2002-08-28
NO20010628D0 (no) 2001-02-06
ES2220110T3 (es) 2004-12-01
AR020001A1 (es) 2002-03-27
EE200100074A (et) 2002-06-17
DE69916457T2 (de) 2005-04-14
EA200100105A1 (ru) 2001-08-27
US6498174B1 (en) 2002-12-24
JP2002522426A (ja) 2002-07-23
AP2001002066A0 (en) 2001-03-31
BR9912866A (pt) 2001-10-30
KR20010085340A (ko) 2001-09-07
TR200100372T2 (tr) 2001-09-21
ID29543A (id) 2001-09-06
PE20000947A1 (es) 2000-09-22
CA2339773A1 (fr) 2000-02-17
CO5070570A1 (es) 2001-08-28
CZ2001490A3 (cs) 2001-08-15
PL345882A1 (en) 2002-01-14
ATE264313T1 (de) 2004-04-15
WO2000008002A1 (fr) 2000-02-17
ZA200100983B (en) 2002-03-05
EP1102757A1 (fr) 2001-05-30
IL141248A0 (en) 2002-03-10
CN1321152A (zh) 2001-11-07
GB9817118D0 (en) 1998-10-07
NO20010628L (no) 2001-04-06
EP1102757B1 (fr) 2004-04-14
SK1962001A3 (en) 2001-11-06
IS5840A (is) 2001-02-05
HRP20010095A2 (en) 2002-02-28
AU5731099A (en) 2000-02-28
HUP0103469A2 (hu) 2002-01-28

Similar Documents

Publication Publication Date Title
MA26668A1 (fr) ACTIVATEURS DE hPPARy ET hPPARa
DE69831755D1 (de) Optoakustische kontrastmittel und anwendungsverfahren
FI990466A0 (fi) Aktivaattorit ja laite
ID23575A (id) Pirazolopirimidina-pirazolopirimidina dan pirazolotriazina-pirazolotriazina
DE69738197D1 (de) Azolotriazine und pyrimidine
CY2012029I2 (el) Nεα μορφη της 5-ομεπραζολης
PT1108039E (pt) Genes de alongases e suas utilizações
ID29591A (id) Senyawa-senyawa kuinolina dan kuinoksalina
ATA106797A (de) Anordnung mit bauteilen und bauteile
DE69924002D1 (de) Kompressions-abgestimmtes bragggitter und kompressions-abgestimmter laser
DE69721533D1 (de) Bekleidungsstück
DE69842210D1 (de) Einführvorrichtung Und Einführungssatz
ID22956A (id) Sintesa disulfida dan polisulfida organik
ID24458A (id) Modifikasi rheologi in-sito poliolefin
DE69831750D1 (de) Biozide und biozide tücher
DE69904731D1 (de) Feinzerkleinerer und feinzerkleinerungsverfahren
PT927183E (pt) Inibidores espirociclicos de metaloproteases
DE69836329D1 (de) Schneller und hochverstärkender operationsverstärker
ID28025A (id) Metode pembuatan aminonitril dan diamina
DE69916694D1 (de) 2-Hydroxy-5-methyl-hexan-3-on und 3-hydroxy-5-methyl-hexan-2-on
ID23258A (id) Penarik pemberian-menyilang dan metodenya
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
ID16838A (id) Komposisi dekafluoropentana
ID28797A (id) Tioredoksin dan pemrosesan biji-bijian
ATE231489T1 (de) N-sulphonyl und n-sulphinyl phenylglycinamide